Improving End Results In Phase II Through Media Optimization

By Hunter Malanson, Staff Scientist, Field Applications at Thermo Fisher Scientific Bioproduction Cell Culture, and Herb Crosby, Senior Account Manager, Thermo Fisher Scientific

Advances in biomedical research over the last decade have resulted in the development of innovative drug products to address a wide range of unmet medical needs. For example, cell and gene therapy is an emerging area of the market, but the current media options available for AAV production are not producing the viral yields needed to move gene therapy forward at a faster pace. Even traditional CHO-based processes used for the development of monoclonal antibodies and recombinant proteins struggle to achieve the yields necessary to meet the evolving demands of the market. These challenges call for manufacturers to identify not only what new capabilities and resources they need to get ahead but also how to optimize current processes to fuel growth.